Calverley PMA, Page C, Dal Negro RW, et al. - Given that erdosteine, a muco-active antioxidant that changes bacterial adhesiveness, resulted in a decrease in the rate and duration of exacerbations in moderate and severe COPD with a history of exacerbations in a multi-national randomized, placebo-controlled study named the RESTORE study, researchers focused on the extent of benefit that can be provided by this drug in patients with less severe disease. For this purpose, they assessed exacerbation rate and duration, time to first exacerbation, and exacerbation-free time in this post hoc analysis performed on the 254 RESTORE participants with spirometrically-defined moderate COPD (post-bronchodilator forced expiratory volume in 1 second 50–79% predicted). Erdosteine 300 mg twice daily (n = 126) or placebo (n = 128) was given to patients for 12 months in addition to usual COPD therapy. Findings revealed that the number of mild, and duration of all, exacerbations were reduced as a result of treatment with erdosteine added to usual COPD maintenance therapy in patients with moderate COPD and a history of exacerbations.